Vaxcyte Inc
PCVX33.120USD
+0.100+0.30%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
4.27BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Vaxcyte Inc Unternehmen
Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Company’s next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.
Unternehmensinformationen
BörsenkürzelPCVX
Name des UnternehmensVaxcyte Inc
IPO-datumJun 12, 2020
CEOMr. Grant E. Pickering
Anzahl der mitarbeiter414
WertpapierartOrdinary Share
GeschäftsjahresendeJun 12
Addresse825 Industrial Road, Ste. 300
StadtSAN CARLOS
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl94070
Telefon16508370111
Websitehttps://vaxcyte.com/
BörsenkürzelPCVX
IPO-datumJun 12, 2020
CEOMr. Grant E. Pickering
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Grant E. Pickering
Mr. Grant E. Pickering
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
676.65K
+3.13%
Mr. Andrew L. Guggenhime
Mr. Andrew L. Guggenhime
President, Chief Financial Officer
President, Chief Financial Officer
83.56K
+6.06%
Mr. James (Jim) Wassil
Mr. James (Jim) Wassil
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
34.31K
+21.13%
Mr. Mikhail Eydelman, J.D.
Mr. Mikhail Eydelman, J.D.
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
12.60K
-28.82%
Dr. Carlos V. Paya, M.D., Ph.D.
Dr. Carlos V. Paya, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
8.67K
+54.06%
Ms. Teri Loxam
Ms. Teri Loxam
Independent Director
Independent Director
8.67K
+54.06%
Mr. Jacks Lee
Mr. Jacks Lee
Independent Director
Independent Director
3.04K
--
Mr. John P. Furey
Mr. John P. Furey
Independent Director
Independent Director
3.04K
--
Dr. Olivier Brandicourt
Dr. Olivier Brandicourt
Independent Director
Independent Director
1.15K
--
Dr. Heath Lukatch, Ph.D.
Dr. Heath Lukatch, Ph.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Grant E. Pickering
Mr. Grant E. Pickering
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
676.65K
+3.13%
Mr. Andrew L. Guggenhime
Mr. Andrew L. Guggenhime
President, Chief Financial Officer
President, Chief Financial Officer
83.56K
+6.06%
Mr. James (Jim) Wassil
Mr. James (Jim) Wassil
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
34.31K
+21.13%
Mr. Mikhail Eydelman, J.D.
Mr. Mikhail Eydelman, J.D.
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
12.60K
-28.82%
Dr. Carlos V. Paya, M.D., Ph.D.
Dr. Carlos V. Paya, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
8.67K
+54.06%
Ms. Teri Loxam
Ms. Teri Loxam
Independent Director
Independent Director
8.67K
+54.06%
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Janus Henderson Investors
11.27%
RA Capital Management, LP
9.45%
The Vanguard Group, Inc.
9.32%
Fidelity Management & Research Company LLC
8.31%
BlackRock Institutional Trust Company, N.A.
7.08%
Other
54.57%
Aktionäre
Aktionäre
Anteil
Janus Henderson Investors
11.27%
RA Capital Management, LP
9.45%
The Vanguard Group, Inc.
9.32%
Fidelity Management & Research Company LLC
8.31%
BlackRock Institutional Trust Company, N.A.
7.08%
Other
54.57%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
47.62%
Investment Advisor/Hedge Fund
40.88%
Hedge Fund
12.35%
Venture Capital
10.72%
Research Firm
1.95%
Private Equity
0.97%
Sovereign Wealth Fund
0.85%
Bank and Trust
0.73%
Individual Investor
0.70%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
652
151.34M
117.31%
-374.47K
2025Q1
669
149.26M
115.73%
-5.52M
2024Q4
629
143.44M
111.44%
-3.61M
2024Q3
579
138.80M
114.99%
+5.28M
2024Q2
508
125.57M
113.86%
-5.08M
2024Q1
487
122.06M
113.01%
+8.05M
2023Q4
444
106.09M
111.72%
-6.02M
2023Q3
417
110.70M
121.97%
-7.51M
2023Q2
397
109.13M
122.07%
+11.09M
2023Q1
366
92.70M
119.26%
-1.36M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Janus Henderson Investors
14.54M
11.27%
+2.77M
+23.58%
Apr 30, 2025
RA Capital Management, LP
12.19M
9.45%
+3.50M
+40.28%
Mar 31, 2025
The Vanguard Group, Inc.
12.02M
9.32%
+82.12K
+0.69%
Mar 31, 2025
Fidelity Management & Research Company LLC
10.73M
8.31%
-632.25K
-5.57%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
9.13M
7.08%
-112.81K
-1.22%
Mar 31, 2025
Wellington Management Company, LLP
6.42M
4.97%
+1.97M
+44.39%
Mar 31, 2025
Capital Research Global Investors
6.11M
4.74%
-100.42K
-1.62%
Mar 31, 2025
State Street Global Advisors (US)
4.41M
3.42%
-131.72K
-2.90%
Mar 31, 2025
T. Rowe Price Associates, Inc.
3.44M
2.66%
-429.53K
-11.11%
Mar 31, 2025
Kynam Capital Management LP
3.20M
2.48%
+863.20K
+36.94%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
ALPS Medical Breakthroughs ETF
2.84%
Harbor Health Care ETF
2.75%
SPDR S&P Biotech ETF
1.36%
Virtus LifeSci Biotech Clinical Trials ETF
0.85%
Direxion Daily S&P Biotech Bull 3X Shares
0.77%
Invesco Nasdaq Biotechnology ETF
0.47%
ProShares Ultra Nasdaq Biotechnology
0.47%
iShares Biotechnology ETF
0.42%
Nuveen ESG Small-Cap ETF
0.36%
JPMorgan Fundamental Data Science Small Core ETF
0.36%
Mehr Anzeigen
ALPS Medical Breakthroughs ETF
Anteil2.84%
Harbor Health Care ETF
Anteil2.75%
SPDR S&P Biotech ETF
Anteil1.36%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil0.85%
Direxion Daily S&P Biotech Bull 3X Shares
Anteil0.77%
Invesco Nasdaq Biotechnology ETF
Anteil0.47%
ProShares Ultra Nasdaq Biotechnology
Anteil0.47%
iShares Biotechnology ETF
Anteil0.42%
Nuveen ESG Small-Cap ETF
Anteil0.36%
JPMorgan Fundamental Data Science Small Core ETF
Anteil0.36%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
